Jonathan Halford to Double-Blind Method
This is a "connection" page, showing publications Jonathan Halford has written about Double-Blind Method.
Connection Strength
0.355
-
A phase 1b/2a study of soticlestat as adjunctive therapy in participants with developmental and/or epileptic encephalopathies. Epilepsy Res. 2021 08; 174:106646.
Score: 0.138
-
A randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of adjunctive carisbamate treatment in patients with partial-onset seizures. Epilepsia. 2011 Apr; 52(4):816-25.
Score: 0.068
-
Long-term individual retention with cenobamate in adults with focal seizures: Pooled data from the clinical development program. Epilepsia. 2022 01; 63(1):139-149.
Score: 0.036
-
Add-on cannabidiol in patients with Dravet syndrome: Results of a long-term open-label extension trial. Epilepsia. 2021 10; 62(10):2505-2517.
Score: 0.035
-
Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia. 2020 06; 61(6):1099-1108.
Score: 0.032
-
Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study. Epilepsia. 2019 03; 60(3):419-428.
Score: 0.030
-
Carisbamate as adjunctive treatment of partial onset seizures in adults in two randomized, placebo-controlled trials. Epilepsia. 2010 Mar; 51(3):333-43.
Score: 0.016